Last reviewed · How we verify
Remifentanil TCI
At a glance
| Generic name | Remifentanil TCI |
|---|---|
| Also known as | REMI - target control infusion |
| Sponsor | Scarlata, Simone, M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- FASt Track in Elective Neurosurgery: the Role of Low Propofol Bis-NOL Guided General Anaesthesia for Full, Early and Safe Awakening
- The Effects of Three Different Anesthetic Methods on Postoperative Agitation (NA)
- Comparison of the Effects of Total Intravenous Anaesthesia With Target-Controlled Infusion (TCI) and Inhalation Anaesthesia on Airway Complications During Extubation and in the Early Postoperative Period in Thyroidectomy Surgery (NA)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Oxidative Stress Effects of TIVA, CIVA, and Balanced Anesthesia in VATS (NA)
- Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil TCI CI brief — competitive landscape report
- Remifentanil TCI updates RSS · CI watch RSS
- Scarlata, Simone, M.D. portfolio CI